Navigation Links
ChromaDex® Announces Management Changes
Date:2/17/2012

IRVINE, Calif., Feb. 17, 2012 /PRNewswire/ -- ChromaDex Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries and marketer of BluScience™ (www.bluscience.com), its recently launched line of dietary supplements, announced today that William F. Spengler has elected to step down from his positions of President and Director of ChromaDex to pursue other business interests. It is anticipated that Jeffrey Himmel, who was recently appointed as CEO of ChromaDex, will also assume the role and title of President.

(Logo:  http://photos.prnewswire.com/prnh/20110830/LA59283LOGO)

Commenting on the announcement, Mr. Spengler stated, "With the company's business plan unfolding nicely and a successful round of equity financing recently completed, ChromaDex is now well positioned for sustained growth. I believe that the company has a bright future ahead of it."

Frank Jaksch, ChromaDex Founder and Chief Science Officer commented, "On behalf of the Board and our employees, I want to thank Bill for his many contributions to the company. All of us at ChromaDex wish him great success in his future endeavors."

About ChromaDex®:
ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an expanding pipeline of new ingredients, including its pTeroPure® (www.pteropure.com) pterostilbene for which it has worldwide, exclusive patent pending rights. The company recently launched its BluScience™ line of dietary supplements. Capitalizing on the diverse potential applications of the product, ChromaDex is also developing pTeroPure for the skincare and pharmaceutical markets, among others. pTeroPure is currently being studied in a human clinical trial at the University of Mississippi.

For more information about pTeroPure, visit www.pteropure.com or call 949-600-9694.

Forward-Looking Statements:
Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies' filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

ChromaDex Investor Contact:
Liviakis Financial Communications, Inc.
John M. Liviakis, President                                                   
415-389-4670
John@Liviakis.com

Institutions and Analysts Contact:
The Del Mar Consulting Group, Inc.
Robert B. Prag, President
858-794-9500
bprag@delmarconsulting.com

ChromaDex/BluScience Contact:
Jeffrey Himmel, CEO
949-419-0288
jsh@chromadex.com


'/>"/>
SOURCE ChromaDex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. ChromaDex® Expands National Launch of its BluScience™ Line of Dietary Supplements Through McKesson
2. NIAID announces 25 new awards to develop radiation countermeasures
3. Aware Announces Q3 2008 Earnings Conference Call
4. Governor Doyle announces historic genomic research collaboration
5. BIO-key(R) Announces Additional $245,000 in Third Quarter Public Safety Orders
6. NARSAD announces 2008 Prizes for Outstanding Achievement in Research on Mental Health Disorders
7. Parkinsons Disease Foundation announces award of $150,000
8. Jefferson Department of Surgery announces new pancreas tumor registry
9. NAS announces initiative to connect entertainment industry with top experts
10. Elsevier announces winners of 3rd Annual Scopus Young Indian Scientist Award
11. VUANCE Announces Crime Scene Security and Evidentiary Tracking Development Project
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... YORK , Feb. 8, 2017 About ... individual,s voice to match it against a stored ... such as pitch, cadence, and tone are compared ... require minimal hardware installation, as most PCs already ... for different transactions. Voice recognition biometrics are most ...
(Date:2/7/2017)... , Feb. 7, 2017   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... , its innovative, highly flexible and award winning ... customers. iMedNet is a proven Software-as-a-Service ... Electronic Data Capture (EDC), but also delivers an entire ...
(Date:2/3/2017)... , Feb. 3, 2017 A new independent ... Strategy Partners, LLP (IdSP) . Designed to fill a ... complex identity market, founding partners Mark Crego ... combined years just in identity expertise that span federal ... non-profit leadership. The Crego-Kephart combined expertise has a common ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... 2017   Biostage, Inc. (Nasdaq: ... developing bioengineered organ implants to treat cancers and other ... today the closing on February 15, 2017 of its ... stock and warrants to purchase 20,000,000 shares of common ... offering was priced at $0.40 per share of common ...
(Date:2/16/2017)... , Feb. 16, 2017  Dermata Therapeutics, ... products to treat a variety of dermatological diseases, ... Series 1a financing and entered into a $5 ...  Dermata intends to use the capital for general ... major advancements in the treatment of serious diseases ...
(Date:2/16/2017)... Pa. , Feb. 16, 2017  Windtree ... biotechnology company focusing on developing aerosolized KL4 surfactant ... from a preclinical influenza study showed that aerosolized ... survival in a well-established preclinical animal model. The ... a growing body of evidence that supports the ...
(Date:2/16/2017)... ... February 16, 2017 , ... ... extended its industry leading Biochemistry Services specifically targeting the rapidly growing needs ... methods for the biochemical and biosimilar characterization , product-related impurity characterization, ...
Breaking Biology Technology: